Novo Nordisk plans to submit weekly growth hormone for approval in H1

Novo Nordisk and Ascendis Pharma could soon face each other on the market for treating children with growth hormone deficiency, as the Danish pharmaceutical giant is intending to file its candidate for approval in the US where latter company is already present.
Photo: Kevin Grønnemann
Photo: Kevin Grønnemann
by MARKETWIRE & MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen

Novo Nordisk is planning to submit its once-weekly growth hormone deficiency (GHD) treatment for children, Sogroya, for regulatory approval in the first half of 2022, the company announces in its financial report on Wednesday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading